For more than 30 years, we’ve driven industry-leading advances in genetics. Myriad completed the initial cloning of BRCA1 and BRCA2 in the 1990s, and today we’re advancing our understanding of homologous recombination deficiency and the genetics of cancer risk — but we’re just getting started.

Our extensive regulatory work throughout the United States, Europe and Japan uniquely positions Myriad as a valuable, experienced partner in navigating regulatory agencies worldwide.

With labs in the U.S. and a partnership in China, Myriad can receive and test samples from all over the world, benefitting patients, researchers, physicians, and pharmaceutical companies around the globe.